Released Nov 12, 2014, before the open
10-Q filed Nov 12, 2014, 43 days after period end · 0001104659-14-079407
Q3 2014 · 10-Q
Revenue—
Net Income-$6.60M-$6.60M N/M vs Q3 2013N/M vs Q2 2014
EPS Diluted-$0.32-$0.32 N/M vs Q3 2013N/M vs Q2 2014
Operating Income-$5,984,000N/M
Operating Cash Flowderived-$5,521,000N/M
Free Cash Flowderived-$5,708,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2014 | Q3 2013 | Q3 2012 |
|---|---|---|---|
| Revenue | — | $209.00K | $528.00K |
| Net Income | -$6.60M | -$6.07M | -$4.11M |
| EPS Diluted | -$0.32 | -$4.81 | -$3.51 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR